Estados financieros detallados de Centessa Pharmaceuticals plc (CNTA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $40.50, CNTA presenta beneficios negativos (P/E no significativo) y un ROE del -60.37%. La capitalización bursátil es de $6.3B.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | $6.9M | 0 | $15.0M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | $6.9M | 0 | $15.0M |
| I+D | $4.3M | $9.3M | $96.3M | $155.1M | $124.4M | $150.2M | $172.2M |
| Generales y Administrativos | $790000 | $1.1M | $43.0M | $55.2M | $53.7M | $50.8M | $50.5M |
| Gastos Operativos | $5.1M | $10.4M | $374.9M | $212.3M | $178.1M | $201.1M | $222.7M |
| Beneficio Operativo | -$5.1M | -$10.4M | -$374.9M | -$212.3M | -$171.3M | -$201.1M | -$207.7M |
| EBITDA | -$5.0M | -$10.3M | -$139.3M | -$209.5M | -$165.4M | -$221.9M | -$183.3M |
| Gastos por Intereses | $118000 | $378000 | $2.5M | $7.3M | $9.9M | $10.1M | $11.5M |
| Beneficio Antes de Impuestos | -$5.1M | -$10.7M | -$381.8M | -$217.0M | -$176.1M | -$232.9M | -$195.7M |
| Impuestos | 0 | 0 | $114000 | -$747000 | -$25.1M | $2.8M | $1.8M |
| Beneficio Neto | -$5.3M | -$10.7M | -$381.9M | -$216.2M | -$151.1M | -$235.8M | -$197.5M |
| BPA | $-0.05 | $-0.08 | $-4.24 | $-2.31 | $-1.57 | $-2.06 | $-1.46 |
| BPA Diluido | $-0.05 | $-0.08 | $-4.24 | $-2.31 | $-1.57 | $-2.06 | $-1.46 |
| Acciones en Circulación (Diluidas) | $106.5M | $70.9M | $90.0M | $93.4M | $96.2M | $114.5M | $135.7M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | -$238599 |
| Beneficio Operativo | -$54.7M | -$53.8M | -$68.5M | -$79.8M |
| EBITDA | -$46.5M | -$51.6M | -$87.1M | -$75.4M |
| Beneficio Neto | -$50.3M | -$54.9M | -$66.2M | -$79.2M |
| BPA | $-0.38 | $-0.41 | $-0.47 | $-0.52 |
| BPA Diluido | $-0.38 | $-0.41 | $-0.47 | $-0.52 |
Balance (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $7.2M | $595.1M | $393.6M | $128.0M | $383.2M | $61.3M |
| Inversiones a Corto | 0 | 0 | 0 | $128.5M | $99.0M | $233.3M |
| Cuentas por Cobrar | 0 | $16.8M | $26.7M | $39.1M | $45.3M | $60.3M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $11.2M | $628.8M | $437.7M | $315.1M | $536.4M | $367.9M |
| Inmovilizado Material | 0 | $162000 | $1.2M | $13.0M | $11.8M | $10.9M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $11.7M | $629.6M | $444.3M | $360.2M | $576.8M | $687.5M |
| Cuentas por Pagar | $1.0M | $8.1M | $13.8M | $11.8M | $7.1M | $7.6M |
| Deuda a Corto | $5.6M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $8.6M | $24.6M | $38.3M | $39.4M | $58.0M | $42.9M |
| Deuda a Largo | 0 | $75.7M | $69.8M | $75.7M | $108.9M | $7.6M |
| Pasivos Totales | $8.6M | $138.1M | $108.1M | $124.0M | $175.3M | $160.6M |
| Reservas | -$23.8M | -$385.7M | -$601.9M | -$752.9M | -$988.7M | -$1.19B |
| Patrimonio Neto | $3.1M | $491.6M | $336.2M | $236.2M | $401.5M | $526.9M |
| Deuda Total | $5.6M | $75.7M | $69.8M | $84.6M | $117.2M | $7.6M |
| Deuda Neta | -$1.6M | -$519.4M | -$323.8M | -$172.0M | -$365.0M | -$287.0M |
| Capital Circulante | $2.5M | $604.1M | $399.4M | $275.7M | $478.4M | $324.9M |
Balance (Trimestral)
| Año | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 |
|---|
| Caja y Equivalentes | $44.2M | $50.8M | $61.3M | $62.4M |
| Activos Totales | $492.1M | $448.3M | $687.5M | $641.8M |
| Pasivos Totales | $147.2M | $146.7M | $160.6M | $154.4M |
| Patrimonio Neto | $344.9M | $301.6M | $526.9M | $487.3M |
| Deuda Total | $118.1M | $118.3M | $7.6M | $7.4M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$5.1M | -$10.7M | -$381.9M | -$216.2M | -$151.1M | -$235.8M | -$197.5M |
| Amortizaciones | $6000 | 0 | $33995 | $131000 | $810000 | $942000 | $921000 |
| Compensación en Acciones | $236000 | $336000 | 0 | $25.0M | $29.4M | $33.5M | $31.0M |
| Cambio en Capital Circulante | -$1.0M | -$489000 | -$5.4M | -$2.8M | -$18.9M | $22.1M | -$51.2M |
| Flujo de Caja Operativo | -$5.8M | -$10.6M | -$136.1M | -$200.5M | -$160.3M | -$142.1M | -$193.8M |
| Inversiones (CapEx) | 0 | 0 | -$185982 | -$1.1M | -$169000 | -$34000 | -$371000 |
| Adquisiciones | 0 | 0 | $63.4M | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | -$11998 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$5.8M | -$10.6M | -$136.3M | -$201.7M | -$160.5M | -$142.1M | -$194.2M |
Flujo de Caja (Trimestral)
| Año | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 |
|---|
| Flujo de Caja Operativo | -$22.5M | -$58.3M | -$55.8M | -$72.2M |
| Inversiones (CapEx) | -$126000 | -$234000 | -$10996 | 0 |
| Flujo de Caja Libre | -$22.6M | -$58.5M | -$55.8M | -$72.2M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $7.9M | $7.2M | $7.9M | $10.6M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | -100.0% | |
| Crecimiento Beneficio Neto (anual) | | -101.8% | -3481.5% | +43.4% | +30.1% | -56.0% | +16.2% |
| Crecimiento BPA (anual) | | -56.7% | -5356.9% | +45.5% | +32.0% | -31.2% | +29.1% |
| Cambio en Acciones (anual) | | -33.4% | +26.9% | +3.8% | +3.0% | +19.0% | +18.6% |
| Crecimiento FCF (anual) | | -82.5% | -1182.5% | -47.9% | +20.4% | +11.5% | -36.7% |
| Margen Bruto | | | | | 100.0% | | 100.0% |
| Margen Operativo | | | | | -2499.4% | | -1384.6% |
| Margen EBITDA | | | | | -2413.9% | | -1222.2% |
| Margen Neto | | | | | -2204.7% | | -1316.9% |
| Margen FCF | | | | | -2342.2% | | -1294.6% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | 0.3% | 14.2% | -1.2% | -0.9% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.05 | $-0.15 | $-1.51 | $-2.16 | $-1.67 | $-1.24 | $-1.43 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $106.5M | $70.9M | $90.0M | $93.4M | $96.2M | $114.5M | $135.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -60.37% |
| Rentabilidad sobre capital invertido | -42.41% |
| Rentabilidad sobre activos | -39.05% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.02 |
| Ratio corriente | 9.53 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 9.85 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -438.51 | -279.92 | -2.66 | -1.34 | -5.07 | -8.13 | -17.13 |
| P/VC | 0.00 | 497.70 | 2.06 | 0.86 | 3.24 | 4.78 | 6.44 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 111.71 | 0.00 | 226.28 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 100.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -2499.4% | 0.0% | -1384.6% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -2204.7% | 0.0% | -1316.9% |